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background: The increasing prevalence of obesity and diabetes has dramatically increased the burden of cardiovascular diseases. Recent studies 
have highlighted the intimate link between metabolic diseases and adipose tissue inflammation. Interestingly, adipsin/complement factor D is 
an adipose-specific immune factor deficient in multiple models of obesity. Adipsin controls the rate-limiting step in the alternative complement 
pathway. Taken together, this places adipsin as a prime candidate to coordinate adipose tissue inflammation and the ensuing metabolic 
consequences of obesity. Adipsin may be the key molecular switch controlling cardiometabolic diseases. The aim of this study was to determine the 
role of adipsin in metabolic diseases.
Methods: Wild-type (WT) and adipsin knockout (KO) mice were assayed in metabolic studies. Serum adipsin was measured in patients undergoing 
elective abdominal surgery.
results: Adipsin KO animals showed attenuated weight gain on a high fat diet (WT 48.1 ± 1.1, KO 46.4 ± 1.2 g, p < 0.01). We found decreased 
infiltration of adipose tissue macrophages in adipsin KO animals (WT 1.0 ± 0.2, KO 0.5 ± 0.1 fold, p < 0.05). Despite the diminished inflammatory 
response and adiposity, adipsin KO mice surprisingly displayed worsened glucose tolerance (WT 270 ± 14, KO 360 ± 21 mg/dl, p < 0.01). We traced 
the exacerbated diabetic phenotype of adipsin KO animals to insulinopenia (WT 0.8 ± 0.2, KO 0.3 ± 0.1 ng/ml, p < 0.05). Accordingly, isolated islets 
from adipsin KO animals displayed deficient glucose-stimulated insulin secretion. As proof of concept, replenishment of adipsin to diabetic db/db 
mice effectively normalized hyperglycemia by boosting insulin secretion. We further identify C3a, a direct peptide product of adipsin catalytic activity, 
as a novel and potent insulin secretagogue. Finally, we show that type 2 diabetes mellitus patients with β cell failure are also deficient in adipsin.
conclusions: The adipsin pathway is a newly identified immune regulator of metabolic diseases, connecting healthy adipose actions to sustain β 
cell function in systemic diseases. Manipulation of this molecular switch may serve as a novel therapy in cardiometabolic diseases.
